β-Blockers Improve Presinusoidal Portal Hypertension

12Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

Background: Presinusoidal portal hypertension is a clinically important cause of gastric and gastroesophageal varices. Whereas β-blockers have an established prophylactic role against bleeding from esophageal and gastric varices in portal hypertension due to cirrhosis, the effect on presinusoidal portal hypertension is unknown. Aims: To evaluate the hemodynamic effect of β-blockers in non-cirrhotic patients with presinusoidal portal hypertension. Methods: We measured the blood pressure gradient from spleen pulp to free hepatic vein in 12 patients with presinusoidal portal hypertension by combined hepatic vein catheterization and spleen pulp puncture while on and off β-blocker treatment (random sequence). Results: The β-blockers reduced the gradient from a mean off-treatment value of 32 mm Hg to a on-treatment value of 26 mm Hg (P < 0.05) with a reduction of at least 20% in five patients (42%). Conclusions: β-blocker treatment caused a clinically significant reduction in the pressure gradient from spleen pulp to the free hepatic vein. This finding supports the recommendation for prophylactic β-blockage in patients with presinusoidal portal hypertension.

Cite

CITATION STYLE

APA

Sørensen, M., Larsen, L. P., Villadsen, G. E., Aagaard, N. K., Grønbæk, H., Keiding, S., & Vilstrup, H. (2018). β-Blockers Improve Presinusoidal Portal Hypertension. Digestive Diseases and Sciences, 63(11), 3153–3157. https://doi.org/10.1007/s10620-018-5186-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free